216 results about "CpG site" patented technology

A method and system for determining one or more sources of a cell free deoxyribonucleic acid (cfDNA) test sample from a test subject. The cfDNA test sample contains a plurality of deoxyribonucleic acid (DNA) molecules with numerous CpG sites that may be methylated or unmethylated. A trained deconvolution model comprises a plurality of methylation parameters, including a methylation level at each CpG site for each source, and a function relating a sample vector as input and a source of origin prediction as output. The method generates a test sample vector comprising a site methylation metric relating to DNA molecules from the test sample that are methylated at that CpG site. The method inputs the test sample vector into the trained deconvolution model to generate a source of origin prediction indicating a predicted DNA molecule contribution of each source.

The invention provides an application of the methylation level of a CpG site combination in deducing the physiological age of an individual. The CpG site combination is selected from at least two of the group consisting of cg25410668, cg16867657, cg22454769, cg08097417, cg21572722, cg17268658, cg23606718, cg03607117, cg24724428, cg13552692, cg04875128, cg14692377, cg00481951, cg07547549, cg06639320 and cg07553761. The invention further provides a kit for detecting Individual physiological age deduction can be realized based on the CpG site combination, and a solution is provided for quick, convenient and accurate physiological age deduction in forensic actual combat application.

The invention discloses a biomarker combination for predicting calendar age, a model and application of the biomarker combination. 57 kinds of DNA methylated CpG sites screened from many elderly subjects are creatively introduced, through multiple detection and large-scale parallel DNA sequencing, operation is easy, the result is highly repeatable, and the age prediction model constructed based on the method is good in stability and accuracy and high in sensitivity and has good application prospects. Calendar age can be predicted from trace blood samples associated with forensic cases.

The invention relates to a method for determining at least part of the cellular composition of at least one biological sample comprising leukocytes, wherein the proportion of at least one type of leukocyte is determined based on the identified methylation levels, in order to predict the relative distribution of that type of leukocyte in the sample. The invention further relates to the use of at least one artificial nucleic acid molecule for determining at least part of the cellular composition of a biological sample comprising leukocytes according to the above-mentioned method. In the context of the invention, the following CpG sites according to the invention with cell-type-specific methylation could be identified: cg22381196 (DHODH), cg12483340 (TMEM87A), cg06270401 (DYRK4), cg23054181 (FAM169BP), cg26076724 (RP11-146I2.2), cg12249234 (KSR1), cg04468741 (MICAL2), cg05074138 (CTLA4), cg05705140 (LINC01237), cg15564619 (SKI), cg11531557 (HMBOX1), cg02212339 (TRPV1), cg22488278 (ZFYVE28), cg02240030 (MAD1L1) and cg24408769 (JARID2).

The present invention discloses the application of a molecular marker methylation level detection reagent for primary hepatocellular carcinoma in the preparation of a detection reagent product, and belongs to the field of gene detection technology. By screening the methylation level of the CpG site in the detected region and its reverse complementary sequence, it is identified whether the target sample is from a primary hepatocellular carcinoma patient. The methylation level of the CpG site in the above region has good sensitivity and specificity for the screening or auxiliary diagnosis of primary hepatocellular carcinoma, and can be used to distinguish samples from patients with primary hepatocellular carcinoma, samples from patients with benign liver diseases (cirrhosis, hepatitis, etc.) and samples from healthy people. The detection reagent and application of the methylation level of the molecular marker can improve the detection rate of early primary hepatocellular carcinoma.

Systems and method as described herein may determine and use methylation levels associated with various tissues and samples. For example, a method may include receiving sequence reads including methylation statuses at sites of cell-free DNA molecules. The method may further include aligning the sequence reads to N sets of one or more CpG sites or genes. Then, for each set of the N sets of one or more CpG sites or genes, the method may include identifying a group of sequence reads aligning to the set of one or more CpG sites or genes and determining a methylation level using the methylation statuses of the group of sequence reads.

The invention provides a biomarker, a kit and a method for predicting the aging-related physiological age of a mouse, the biomarker comprises a plurality of CpG sites with different methylation levels, and the position information of the CpG sites is as follows: chr10: 122698929, chr11: 22600252, chr12: 86422875, chr13: 49379202, chr14: 55116926, chr15: 86222032, chr16: 87766091, chr17: 55971541, chr1: 109982829 and the like. The method can solve the problem of high cost of detecting the physiological age of the mouse through methylation level in the prior art, and is suitable for the field of animal age detection.

The invention discloses markers for detecting ovarian cancer DNA methylation, application of the markers and an ovarian cancer detection kit, the markers are ZNF551, ZFP41, BHMT, CDKN2A, ATP8A2, ALDH1A3 and TRH, and the seven markers and genome sequences in the range of 90-110bp upstream and downstream of a specific CpG site are protected. The theoretical sensitivity and specificity of the single marker for ovarian cancer patient detection can be close to 90% or above, and the theoretical sensitivity and specificity of all pairwise combinations of the seven markers for ovarian cancer patient detection can be close to 95% or above. Compared with the prior art, the ovarian cancer detection product provided by the invention has the beneficial effects that the detection product is used for detecting the appropriate marker combination, so that the ovarian cancer detection effect that the sensitivity and the specificity are close to 90% or reach 90% or above at the same time is achieved.

The invention relates to methods for diagnosing inflammatory bowel disease (IBD) and for distinguishing between common gastrointestinal disease (principally functional bowel disease / irritable bowel syndrome and coeliac disease) and IBD, especially in children and in subjects with normal levels of C-reactive protein. The methods are based on measuring the methylation level of at least one CpG site in at least one gene.

The invention discloses a high-risk cervical cancer shunt kit based on MassARRAY methylation detection. The kit comprises an amplification primer combination, an extension primer combination, a multiple PCR (Polymerase Chain Reaction) reaction system and an extension reaction system, wherein the amplification primer combination is used for detecting methylation levels of five CpG sites of PAX1, SOX1, MIR124-2 and FAM19A4 genes. According to the kit, hydrosulfite conversion is carried out on DNA of a cervical or near-cervical cell sample, then a MassARRAY technology is combined, specific methylation detection primers are designed, amplification, extension and mass spectrometry are carried out on five CpG sites, and the methylation level is calculated according to methylation C peak HEIGHT data and unmethylated T peak HEIGHT data obtained through mass spectrometry; and finally, predicting the disease risk of the subject according to a methylation detection result. The gene methylation result provided by the invention perfects epigenetics information of gene detection, has the characteristics of large flux, high accuracy, low cost and the like, and can assist clinicians in shunting HPV positive subjects, reduce TCT leak detection and avoid excessive medical treatment.

Disclosed herein are methods and compositions for predicting tumor content e.g., tumor content in a sample and tumor burden of an individual. Generally, methods and compositions involve determining methylation statuses of two or more sequential CpG sites in one or more genomic locations using nucleic acids of the obtained sample. The methylation statuses of the two or more sequential CpG in genomic locations are used to distinguish between reads of nucleic acids that are likely derived from cancer and reads of other nucleic acids that are unlikely to be derived from cancer. Distinguishing reads that are likely derived from cancer enables the prediction of tumor content in a sample.

The present invention relates to a tetracyclic compound and a use thereof. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer, a racemate, a solvate, a pharmaceutically acceptable salt, or a deuterated compound thereof in the preparation of a composition or a formulation for preventing and / or treating tumors. The compound of the present invention has an excellent precise treatment effect on tumors with low or no expression and low or no activity of mitochondrial membrane permeability pores, low or no expression and low or no activity of recombinant peptidylprolyl isomerase F, low or no expression of NNMT gene, high expression of DNA methylases, high expression of UHRF 1, a high methylation level at a nucleotide site of the NNMT gene, and / or a high methylation level at a DNA CpG site of a NNMT gene region.

The invention relates to the technical field of bioinformatics, in particular to a method for identifying an abnormally hypermethylated region in cancer methylation data. The method comprises the following steps: acquiring whole genome methylation sequencing data of a sample to be detected and genome conserved sequence data of primate species; performing density analysis based on a progressive hierarchical scanning strategy on the CpG loci according to the whole genome methylation sequencing data to obtain CpG enriched region data; performing distance calculation including short-range, medium-range and long-range on the genome conservative sequence data, and performing weighted correction on a calculation result according to the CpG enrichment region data to obtain region conservative score data. According to the method, through unsupervised clustering, self-adaptive threshold setting and multi-scale feature extraction, high methylation regions with high regulation and control effects in different cancer types can be more accurately captured.

The invention provides a method for predicting multiple degenerative diseases and screening markers based on DNA methylation, and belongs to the technical field of biological information. The method comprises the following steps: firstly, acquiring DNA methylation data from a GEO database, and screening out CpG loci with non-zero feature importance through a random forest algorithm; performing multi-scale feature extraction on the screened CpG sites by using a multi-scale one-dimensional convolutional neural network, and capturing local and global features; then, 110 key CpG loci related to various degenerative diseases are screened out through interaction network analysis of GO, KEGG and protein; and finally, constructing a multi-classification disease prediction model based on the residual network, and performing classification prediction on neurodegenerative diseases, bone degenerative diseases, breast cancers and health states. According to the invention, the screening accuracy of degenerative diseases is improved, a scientific biomarker screening basis is provided, and support of precise medical treatment and early intervention is facilitated.

The present invention provides an in vitro method for determining the X chromosome reactivation (X-Ra) level of a female subject, the method comprising the steps of (a) determining the methylation status of at least 10 CpG sites of Table 1 in a DNA-containing sample from the female subject; and (b) calculating the fraction of the CpG sites analyzed in step (a) that are hypomethylated. The invention also provides in vitro methods for determining the biological age of a female subject, diagnosis and / or prognosis of an age-related disease or disorder or an infection, and for determining the gestational age of a fetus.

Disclosed are methods of preparing a composition of non-naturally occurring DNA, comprising: (a) extracting DNA from a sample of a subject; (b) contacting the extracted DNA or its derivative with a panel of oligonucleotide probes designed to hybridize to a plurality of preselected genomic regions, thereby generating selected DNA, wherein at least 50% of the preselected genomic regions are CpG regions that each comprises at least 3 CpG sites and a CpG density of at least 0.02 CpG / bp, wherein the preselected genomic regions cover 10-500 Mb of sequence space in human genome, wherein the extracted DNA or its derivative or the selected DNA or its derivative is further treated with an agent or a combination of agents that discriminates between methylated and unmethylated cytosines; and (c) performing high-throughput sequencing on the selected DNA or its derivative and generating sequencing reads.

The invention provides a primer probe composition and a kit for post-operation MRD (minimal residual focus) detection and dynamic monitoring of pancreatic ductal adenocarcinoma (PDAC). The primer probe composition disclosed by the invention is used for amplifying a CpG site enrichment region of a gene mir129-2 promoter region. By using the method provided by the invention, the specific CpG site enrichment region can be specifically amplified in a high methylation state, and cannot be amplified in a low or no methylation state. The kit provided by the invention comprises a methylation primer and a probe of the gene mir129-2, and further comprises a primer and a probe of a reference gene ACTB. The kit can be used for detecting the methylation state of the gene mir129-2 starter region, and the methylation state of the gene mir129-2 starter region can be used as a marker for post-operation MRD detection and dynamic monitoring of pancreatic ductal adenocarcinoma (PDAC), and is used for evaluating the recurrence risk of a post-operation patient of the pancreatic ductal adenocarcinoma (PDAC).

The present invention relates to a nitrogen-containing heterocyclic compound and its use, which has a significantly superior therapeutic effect on tumors with low or no expression of NNMT gene, high expression of DNA methyltransferase, high expression of UHRF1, hypermethylation of nucleotide sites in the NNMT gene and / or hypermethylation of DNA CpG sites in the NNMT gene region. The present invention provides a compound of formula I, or an optical isomer or racemate thereof, or a solvate thereof, or a pharma- ceutically acceptable salt thereof, or a deuterated compound thereof. TIFF2025509620000598.tif83150

The present application relates to a method and system for inferring the age of an individual from semen or a semen stain, and a methylation detection kit, which comprises the following steps: firstly, extracting the genomic DNA of the semen or semen stain of the individual; secondly, performing bisulfite treatment on the genomic DNA; thirdly, selecting a plurality of sites in the CpG sites in the genomic DNA and amplifying the selected CpG sites to obtain the methylation rate of the selected CpG sites; and finally, performing regression analysis on the methylation rate of the selected CpG sites and the age of the individual to construct a regression model for inferring the age of an unknown individual from semen or a semen stain. The average absolute error of the present application reaches 1.68 to 4.44 years.

The present application relates to the technical field of bioinformatics, and particularly relates to a method for constructing a biological age prediction model based on DNA methylation. The method comprises the following steps: obtaining whole genome methylation sequencing data of a human peripheral blood sample; classifying cell subpopulations of the human peripheral blood sample, and performing single-cell RNA sequencing processing on each cell subpopulation to obtain single-cell sequencing data including lymphocytes, neutrophils and monocytes; performing tissue-specific analysis on CpG sites within a range of 2000 base pairs upstream and downstream of each cell subpopulation-specific transcription factor binding site according to the single-cell sequencing data and the whole genome methylation sequencing data to obtain candidate marker site data. The present application can provide strong support for early detection of accelerated aging, prediction of related disease risks and guidance of precision medicine.

The present invention relates to a tetracyclic compound and a use thereof. Specifically, the present invention provides a use of a compound of formula I, or an optical isomer, a racemate, a solvate, a pharmaceutically acceptable salt, or a deuterated compound thereof in the preparation of a composition or a formulation for preventing and / or treating tumors. The compound of the present invention has an excellent precise treatment effect on tumors with low or no expression and low or no activity of mitochondrial membrane permeability pores, low or no expression and low or no activity of recombinant peptidylprolyl isomerase F, low or no expression of NNMT gene, high expression of DNA methylases, high expression of UHRF 1, a high methylation level at a nucleotide site of the NNMT gene, and / or a high methylation level at a DNA CpG site of a NNMT gene region.

The present invention provides a device and a method capable of constructing a model that has high prediction accuracy and is suitable for a specific group from a small number of DNA methylation data items obtained from the specific group while reducing the number of samples required for model construction. A biological age measurement device 1 according to the present invention measures the biological age on the basis of the DNA methylation level. By using, as an explanatory variable matrix (n×p matrix (p≤q)), first explanatory variable information based on DNA methylation information in CpG sites at q points included in DNA of each sample of a first population composed of n samples, and using, as an objective variable vector (n-dimensional), first objective variable information based on biological age information of the n samples, the biological age measurement device 1 performs transfer learning on the basis of a biological age measurement model estimated by a second population different from the first population, and outputs the learning result as a trained biological age measurement model.

The present invention is related to a method of determining suitability of at least one Chinese Hamster Ovary (CHO) test cell line for optimal heterologous protein production, the method comprising:(a) determining a test methylation profile from genomic material obtained from the CHO test cell line; and(b) comparing the test methylation profile obtained from (a) with a reference methylation profile, wherein the reference methylation profile comprises the methylation status of more than one CpG site from at least one CHO reference cell line that displays at least one phenotype of interest for optimal heterologous protein production,wherein a significant similarity in the test methylation profile of (a) compared to the reference methylation profile, is indicative of the CHO test cell line being suitable for optimal heterologous protein production and wherein the test methylation profile and reference methylation profile are from CpG sites from the CHO cell genome and are determined using DNA methylation-bead-based array.

Disclosed are a method for predicting semen quality of a bull, a device therefor, and a computer-readable storage medium. The method screens 83 CpG sites from known methylation profile data of bull sperm based on variability in methylation levels, and constructs an epigenetic clock using elastic net regression with the screened CpG sites. The epigenetic clock is used to predict an age of a subject bull. Semen quality is predicted based on epigenetic age acceleration, defined as a difference between the predicted epigenetic age and a chronological age of the bull, and may be used for selection and breeding of bulls.

The invention belongs to the technical field of information analysis, and particularly relates to a whole genome methylation region splitting method based on a co-methylation state of adjacent CpG loci. On the basis of whole genome methylation sequencing data, methylation regions are split within a whole genome range according to the co-methylation state of adjacent CpG sites, more methylation region information is provided for diagnosis of diseases such as cancers, and the effect of improving the methylation signal-to-noise ratio of the diseases such as the cancers is achieved.

The invention relates to the technical field of judicial expertise, in particular to a segmented blood DNA methylation age prediction method and system based on an SVR model, and the method comprises the steps: collecting a DNA sample of a to-be-evaluated object; measuring the methylation level of a predetermined CpG site on the DNA sample to obtain a methylation level parameter; and predicting the age of the to-be-evaluated object according to the methylation level parameter. In order to solve the problem that the prediction error of a prediction method in the prior art is obviously increased along with the increase of age groups, in the scheme, firstly, the age interval of a to-be-evaluated object is predicted, then a prediction model on the corresponding interval is called in each age interval, and effective point locations screened out in the regression analysis process are combined, so that the prediction accuracy of the to-be-evaluated object is improved. The age of the to-be-evaluated object is accurately predicted, and the influence of the age interval on the age prediction error is improved.

To provide a new method for testing for sensitivity of chemotherapy against colorectal cancer using, as an indicator, a methylation site that has not been conventionally known to be an indicator of responsiveness to chemotherapy of colorectal cancer.SOLUTION: The present invention provides a method for testing for sensitivity of chemotherapy against colorectal cancer, the method using, as an indicator, methylation in at least one site selected from a group consisting of CpG sites comprised in regions (i) to (xvi) in DNA collected from a colorectal cancer patient (the regions (i) to (xvi) are as described herein).SELECTED DRAWING: None

The present invention relates to a method for assessing the prognosis or risk stratification of liver cancer by using a clinical specimen mixed with a normal tissue, wherein at least one CpG site that shows a low methylation level in normal and blood tissues but a high methylation level in only a cancer tissue is measured for methylation level.

The invention belongs to but is not limited to the technical field of biology, and discloses a DNA methylation age prediction method and system based on a uniAge model, and the method comprises the following steps: screening out CpG sites which can be covered by RRBS and a methylation chip at the same time; screening sites from the common CpG sites and training an age prediction model by using DNAme chip data of human peripheral blood; and correcting the DNAme level obtained by sequencing data, aligning the DNAme level with chip data, or independently fitting a model coefficient on the sequencing data by using the screened CpG site. According to the invention, individual age is predicted by using DNAme levels of a plurality of CpG sites of peripheral blood; and training an age prediction model simultaneously applicable to methylation chip data and sequencing data.

A multi-modal pan-cancer early prediction method is disclosed, comprising: collecting cfDNA samples of i cancer populations and healthy populations respectively and extracting methylation data; merging CpG sites based on the methylation data to obtain multiple methylation intervals, screening multiple candidate marker intervals from the multiple methylation intervals, and further screening the multiple candidate marker intervals; training a first prediction model using the multiple candidate marker intervals, training a second prediction model based on the fragmentation characteristics of the chromosomes extracted from the reference genome, and training a third prediction model by extracting the methylation entropy characteristics of the chromosomes; training a multi-modal pan-cancer early prediction model through the cancer population prediction values of the first prediction model, the second prediction model and the third prediction model, which can provide precise joint early screening for lung cancer, intestinal cancer, gastric cancer, liver cancer, esophageal cancer, thyroid cancer and ovarian cancer.